- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 233/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 233/02
Total number of patents in this class: 145
10-year publication summary
|
5
|
9
|
8
|
10
|
11
|
3
|
8
|
7
|
6
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4898 |
5 |
| Allergan, Inc. | 2349 |
5 |
| Covestro Deutschland AG | 2747 |
4 |
| Firmenich SA | 1684 |
3 |
| The University of British Columbia | 1501 |
3 |
| Oncternal Therapeutics, Inc. | 35 |
3 |
| Merck Sharp & Dohme LLC | 3748 |
3 |
| The Regents of the University of California | 19918 |
2 |
| Boehringer Ingelheim International GmbH | 4650 |
2 |
| Toshiba Corporation | 12336 |
2 |
| Sumitomo Chemical Company, Limited | 9046 |
2 |
| President and Fellows of Harvard College | 5976 |
2 |
| Avexxin AS | 46 |
2 |
| Eli Lilly and Company | 3842 |
2 |
| King Faisal University | 914 |
2 |
| Neuropro Therapeutics, Inc. | 20 |
2 |
| Trustees of Dartmouth College | 1085 |
2 |
| GPCP IP Holdings LLC | 1631 |
2 |
| Zealand Pharma A/S | 258 |
2 |
| Nouryon Chemicals International B.V. | 608 |
2 |
| Other owners | 93 |